Miniatura

Fitxers

Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men_ClincalMedicine.pdf (776.23 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-02-12

Llicència de publicació

cc by (c) Alcaraz Asensio, Antonio et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/202098

Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm11040967

Resum

We investigated changes in symptoms and quality of life (QoL) in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving the hexanic extract of Serenoa repens (HESr) and compared results with a matched group on watchful waiting (WW). Data was from a real-world, open-label, prospective, multicenter study. This sub-group analysis included patients with moderate-to-severe symptoms receiving either the HESr 320 mg/daily for six months (HESr) or who remained untreated for LUTS/BPH (WW). Changes in urinary symptoms and QoL were measured by IPSS and BII questionnaires. Two statistical approaches (iterative matching and propensity score pairing) were used to maximize between-group comparability at baseline. Tolerability was assessed in the HESr group. After iterative matching, data for analysis was available for 783 patients (102 WW, 681 HESr). IPSS scores improved by a mean (SD) of 3.8 (4.4) points in the HESr group and by 2.2 (4.5) points in the WW group (p = 0.002). Changes in BII score were 1.8 (2.4) points and 1.0 (2.2) points, respectively (p < 0.001). Three patients (0.9%) treated with the HESr reported mild adverse effects. Moderate-severe LUTS/BPH patients treated for six months with the HESr showed greater improvements in symptoms and QoL than matched patients on WW, with a very low rate of adverse effects.

Matèries

Qualitat de vida, Homes, Malalties de l'aparell urinari

Matèries (anglès)

Quality of life, Men, Diseases of the urinary organs

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ALCARAZ ASENSIO, Antonio, GACCI, Mauro, FICARRA, Vincenzo, MEDINA POLO, José, SALONIA, Andrea, FERNÁNDEZ GÓMEZ, Jesús m., CIUDIN, Alexandru, CASTRO DIAZ, David, RODRÍGUEZ ANTOLÍN, Alfredo, CARBALLIDO RODRÍGUEZ, Joaquín, CÓZAR OLMO, José m., BÚCARTERRADES, Santiago, PÉREZ LEÓN, Noemí, BRENES BERMÚDEZ, Francisco j., MOLERO GARCÍA, José m., FERNÁNDEZ-PRO LEDESMA, Antonio, HERDMAN, Michael, MANASANCH, José, ANGULO, Javier c., QUALIPROST Study Group. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study. _Journal of Clinical Medicine_. 2022. Vol. 11, núm. 4, pàgs. 967. [consulta: 25 de febrer de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/202098]

Exportar metadades

JSON - METS

Compartir registre